Brought to you by 
ML Labs acquires Cobra Therapeutics
15 Mar 2000
Executive Summary
ML Laboratories (drug delivery and therapeutics) will acquire Cobra Therapeutics (gene delivery and expression technologies, manufactures DNA-based products) for $12.9mm (UK8mm) in stock. ML Laboratories may pay an additional $19.3mm, depending on the sales of Cobra's products or its assets.
Deal Industry
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ML Labs acquires Cobra Therapeutics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice